Related Experiment Video
Updated: May 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA
None:
As the COVID-19 pandemic waned, Mycoplasma pneumoniae reemerged in the pediatric population in Ohio, USA. The rate of macrolide-resistant M. pneumoniae fluctuated by month, ranging from 0 to 8.7%, and mirrored the azithromycin prescribing rate. Real-time surveillance for macrolide-resistant M. pneumoniae provides accurate information for management of children with these infections.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
06:04Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Related Concept Videos
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Pneumonia I: Introduction